Giuseppe Di Giovanni

List of Publications by Year in Descending Order

150 papers	5,583 citations	40 h-index	70 g-index
183 ext. papers	6,612 ext. citations	5.3 avg, IF	5.92 L-index

#	Paper	IF	Citations
150	Nicotine modulation of the lateral habenula/ventral tegmental area circuit dynamics: An electrophysiological study in rats. *Neuropharmacology*, **2022**, 202, 108859	5.5	1
149	The effect of cannabinoid receptor agonist WIN 55,212-2 on anxiety-like behavior and locomotion in a genetic model of absence seizures in the elevated plus-maze.. *CNS Neuroscience and Therapeutics*, **2022**,	6.8	0
148	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. *Pharmacological Reviews*, **2021**, 73, 310-520	22.5	48
147	Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents. *ACS Chemical Neuroscience*, **2021**, 12, 1716-1736	5.7	3
146	Reciprocal Lateral Hypothalamic and Raphe GABAergic Projections Promote Wakefulness. *Journal of Neuroscience*, **2021**, 41, 4840-4849	6.6	2
145	Lateral Habenula 5-HT Receptor Function Is Altered by Acute and Chronic Nicotine Exposures. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
144	The impact of chronic daily nicotine exposure and its overnight withdrawal on the structure of anxiety-related behaviors in rats: Role of the lateral habenula. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 105, 110131	5.5	9
143	5-HT interaction with other neurotransmitters: An overview. *Progress in Brain Research*, **2021**, 259, 1-5	2.9	2
142	Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics. *Progress in Brain Research*, **2021**, 261, 83-158	2.9	2
141	5-HT/GABA interaction in epilepsy. *Progress in Brain Research*, **2021**, 259, 265-286	2.9	2
140	5-HT/GABA interaction in neurodevelopment and plasticity. *Progress in Brain Research*, **2021**, 259, 287-317	2.9	2
139	Endocannabinoid-serotonin systems interaction in health and disease. *Progress in Brain Research*, **2021**, 259, 83-134	2.9	3
138	Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. *Progress in Brain Research*, **2021**, 261, 161-264	2.9	2
137	Multiple facets of serotonergic modulation. *Progress in Brain Research*, **2021**, 261, 3-39	2.9	2
136	Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures. *Brain*, **2020**, 143, 2341-2368	11.2	44
135	Acute and Chronic Nicotine Exposures Differentially Affect Central Serotonin 2A Receptor Function: Focus on the Lateral Habenula. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
134	Serotonin in Animal Cognition and Behavior. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	59

133	Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain. *Frontiers in Pharmacology*, **2020**, 11, 962	5.6	5
132	Constitutive activity of 5-HT receptors: Factual analysis. *Neuropharmacology*, **2020**, 168, 107967	5.5	27
131	Serotonergic control of excitability: from neuron to networks. *Handbook of Behavioral Neuroscience* , **2020**, 31, 197-215	0.7	2
130	Acute and Chronic Dopaminergic Depletion Differently Affect Motor Thalamic Function. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
129	Comparison between Tail Suspension Swing Test and Standard Rotation Test in Revealing Early Motor Behavioral Changes and Neurodegeneration in 6-OHDA Hemiparkinsonian Rats. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
128	Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats. *Neuropharmacology*, **2020**, 166, 107915	5.5	14
127	T-patterns in the study of movement and behavioral disorders. *Physiology and Behavior*, **2020**, 215, 112790	3.5	4
126	Application of T-pattern analysis in the study of the organization of behavior. *Physiology and Behavior*, **2020**, 227, 113138	3.5	5
125	Effects of chronic nicotine on the temporal structure of anxiety-related behavior in rats tested in hole-board. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2020**, 96, 109731	5.5	6
124	Synergistic action of CB and 5-HT receptors in preventing pilocarpine-induced status epilepticus in rats. *Neurobiology of Disease*, **2019**, 125, 135-145	7.5	17
123	WIN 55,212-2 Reverted Pilocarpine-Induced Status Epilepticus Early Changes of the Interaction among 5-HT/NMDA/CB Receptors in the Rat Hippocampus. *ACS Chemical Neuroscience*, **2019**, 10, 3296-3306	5.7	11
122	Neurochemical impact of the 5-HT receptor agonist WAY-163909 on monoamine tissue content in the rat brain. *Neurochemistry International*, **2019**, 124, 245-255	4.4	17
121	Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. *European Journal of Neuroscience*, **2019**, 49, 805-816	3.5	11
120	Reciprocal interaction between monoaminergic systems and the pedunculopontine nucleus: Implication in the mechanism of L-DOPA. *Neurobiology of Disease*, **2019**, 128, 9-18	7.5	2
119	Combining Quantitative and Qualitative Data in the Study of Feeding Behavior in Male Wistar Rats. *Frontiers in Psychology*, **2019**, 10, 881	3.4	10
118	Effect of the 5-HT Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	8
117	Different Representation Procedures Originated from Multivariate Temporal Pattern Analysis of the Behavioral Response to Pain in Wistar Rats Tested in a Hot-Plate under Morphine. *Brain Sciences*, **2019**, 9,	3.4	1
116	Effects of Substantia Nigra pars compacta lesion on the behavioral sequencing in the 6-OHDA model of Parkinson's disease. *Behavioural Brain Research*, **2019**, 362, 28-35	3.4	10

115	Developmental changes of GABA immunoreactivity in cortico-thalamic networks of an absence seizure model. *Neuropharmacology*, **2018**, 136, 56-67	5.5	6
114	Role of Serotonin2A (5-HT2A) Receptors in Epilepsy **2018**, 375-394		
113	Preferential modulation of the lateral habenula activity by serotonin-2A rather than -2C receptors: Electrophysiological and neuroanatomical evidence. *CNS Neuroscience and Therapeutics*, **2018**, 24, 721-733	6.8	16
112	Cortical drive and thalamic feed-forward inhibition control thalamic output synchrony during absence seizures. *Nature Neuroscience*, **2018**, 21, 744-756	25.5	46
111	Pharmacological Analysis in Favour of a Physiological Role for the Constitutive Activity of 5-HT2A Receptors in Learning **2018**, 3-29		
110	Behavioral fragmentation in the D1CT-7 mouse model of Tourette's syndrome. *CNS Neuroscience and Therapeutics*, **2018**, 24, 703-711	6.8	13
109	TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT receptor pharmacological tool, or none of the above?. *Neuropharmacology*, **2018**, 142, 20-29	5.5	12
108	T-pattern detection and analysis for the discovery of hidden features of behaviour. *Journal of Neuroscience Methods*, **2018**, 310, 24-32	3	38
107	Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms. *Journal of Neuroscience Methods*, **2018**, 308, 205-218	3	19
106	Suppression of Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel Function in Thalamocortical Neurons Prevents Genetically Determined and Pharmacologically Induced Absence Seizures. *Journal of Neuroscience*, **2018**, 38, 6615-6627	6.6	18
105	Does the Serotonin2C receptor segregate circuits of the basal ganglia responding to cingulate cortex stimulation?. *CNS Neuroscience and Therapeutics*, **2018**, 24, 741-744	6.8	8
104	Oscillatory Activity in the Cortex, Motor Thalamus and Nucleus Reticularis Thalami in Acute TTX and Chronic 6-OHDA Dopamine-Depleted Animals. *Frontiers in Neurology*, **2018**, 9, 663	4.1	8
103	Reprint of "Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms". *Journal of Neuroscience Methods*, **2018**, 310, 75-88	3	3
102	Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. *Progress in Neurobiology*, **2017**, 151, 175-236	10.9	99
101	Early Loss of Blood-Brain Barrier Integrity Precedes NOX2 Elevation in the Prefrontal Cortex of an Animal Model of Psychosis. *Molecular Neurobiology*, **2017**, 54, 2031-2044	6.2	29
100	Monoaminergic neuropathology in Alzheimer's disease. *Progress in Neurobiology*, **2017**, 151, 101-138	10.9	137
99	Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry. *Progress in Neurobiology*, **2017**, 151, 57-100	10.9	72
98	The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity. *Scientific Reports*, **2017**, 7, 11152	4.9	27

97	EEG feature extraction using common spatial pattern with spectral graph decomposition **2017**,		1
96	Distinct roles of cortical and pallidal and frequencies in hemiparkinsonian and dyskinetic rats. *Experimental Neurology*, **2016**, 275 Pt 1, 199-208	5.7	20
95	Temporal patterns of rat behaviour in the central platform of the elevated plus maze. Comparative analysis between male subjects of strains with different basal levels of emotionality. *Journal of Neuroscience Methods*, **2016**, 268, 155-62	3	10
94	New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. *Pharmacology & Therapeutics*, **2016**, 157, 125-62	13.9	76
93	Application of T-Pattern Analysis in the Study of Rodent Behavior: Methodological and Experimental Highlights. *Neuromethods*, **2016**, 217-235	0.4	
92	Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs. *Frontiers in Neuroscience*, **2016**, 10, 492	5.1	37
91	Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. *Frontiers in Neuroscience*, **2016**, 10, 541	5.1	35
90	Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. *Biomolecules*, **2016**, 6, 6	5.9	348
89	Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures. *Neuropharmacology*, **2016**, 108, 292-304	5.5	38
88	Hsp60 response in experimental and human temporal lobe epilepsy. *Scientific Reports*, **2015**, 5, 9434	4.9	20
87	Animal Models of Episodic Ataxia Type 1 (EA1) **2015**, 797-807		
86	Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?. *Frontiers in Pharmacology*, **2015**, 6, 46	5.6	73
85	T-pattern analysis for the study of temporal structure of animal and human behavior: a comprehensive review. *Journal of Neuroscience Methods*, **2015**, 239, 34-46	3	79
84	A critical evaluation of the gamma-hydroxybutyrate (GHB) model of absence seizures. *CNS Neuroscience and Therapeutics*, **2015**, 21, 123-40	6.8	30
83	Differential Control by 5-HT and 5-HT1A, 2A, 2C Receptors of Phasic and Tonic GABAA Inhibition in the Visual Thalamus. *CNS Neuroscience and Therapeutics*, **2015**, 21, 967-70	6.8	6
82	The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo. *CNS Neuroscience and Therapeutics*, **2015**, 21, 745-7	6.8	16
81	The central role of aquaporins in the pathophysiology of ischemic stroke. *Frontiers in Cellular Neuroscience*, **2015**, 9, 108	6.1	78
80	Acute nicotine induces anxiety and disrupts temporal pattern organization of rat exploratory behavior in hole-board: a potential role for the lateral habenula. *Frontiers in Cellular Neuroscience*, **2015**, 9, 197	6.1	37

79	Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene. *Frontiers in Physiology*, **2014**, 5, 525	4.6	30
78	Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats. *CNS Neuroscience and Therapeutics*, **2014**, 20, 671-8	6.8	21
77	Oligodendrocyte pathophysiology and treatment strategies in cerebral ischemia. *CNS Neuroscience and Therapeutics*, **2014**, 20, 603-12	6.8	67
76	Cortistatin-14 mediates its anticonvulsant effects via sst2 and sst3 but not ghrelin receptors. *CNS Neuroscience and Therapeutics*, **2014**, 20, 662-70	6.8	9
75	Animal models of tic disorders: a translational perspective. *Journal of Neuroscience Methods*, **2014**, 238, 54-69	3	38
74	Investigating local and long-range neuronal network dynamics by simultaneous optogenetics, reverse microdialysis and silicon probe recordings in vivo. *Journal of Neuroscience Methods*, **2014**, 235, 83-91	3	15
73	N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties. *CNS Neuroscience and Therapeutics*, **2014**, 20, 633-40	6.8	8
72	Monoamine modulation of tonic GABAA inhibition. *Reviews in the Neurosciences*, **2014**, 25, 195-206	4.7	10
71	Predicting dopaminergic effects of L-DOPA in the treatment for Parkinson's disease. *CNS Neuroscience and Therapeutics*, **2014**, 20, 699-701	6.8	8
70	Role(s) of the 5-HT2C receptor in the development of maximal dentate activation in the hippocampus of anesthetized rats. *CNS Neuroscience and Therapeutics*, **2014**, 20, 651-61	6.8	33
69	Role of Central Serotonin Receptors in Nicotine Addiction **2014**, 279-305		1
68	GPCR Modulation of Extrasynapitic GABAA Receptors **2014**, 125-153		2
67	Gain-of-Function of Thalamic Extrasynaptic GABA-A Receptors in Typical Absence Seizures. *Receptors*, **2014**, 223-237		
66	High dose of 8-OH-DPAT decreases maximal dentate gyrus activation and facilitates granular cell plasticity in vivo. *Experimental Brain Research*, **2013**, 230, 441-51	2.3	21
65	5-HT2 receptors-mediated modulation of voltage-gated K+ channels and neurophysiopathological correlates. *Experimental Brain Research*, **2013**, 230, 453-62	2.3	10
64	Serotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy. *Experimental Brain Research*, **2013**, 230, 605-24	2.3	9
63	Essential thalamic contribution to slow waves of natural sleep. *Journal of Neuroscience*, **2013**, 33, 19599-610	6.6	139
62	GABAB Receptors Regulate Extrasynaptic GABAA Receptors. *Journal of Neuroscience*, **2013**, 33, 3780-5	6.6	74

61	Acute nigro-striatal blockade alters cortico-striatal encoding: an in vivo electrophysiological study. *Experimental Neurology*, **2013**, 247, 730-6	5.7	12
60	The role of the serotonergic system at the interface of aggression and suicide. *Neuroscience*, **2013**, 236, 160-85	3.9	73
59	Dopaminergic modulation of tonic but not phasic GABAA-receptor-mediated current in the ventrobasal thalamus of Wistar and GAERS rats. *Experimental Neurology*, **2013**, 247, 1-7	5.7	20
58	Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions. *Experimental Brain Research*, **2013**, 230, 427-39	2.3	38
57	K(+) channelepsy: progress in the neurobiology of potassium channels and epilepsy. *Frontiers in Cellular Neuroscience*, **2013**, 7, 134	6.1	63
56	Are vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy?. *Frontiers in Cellular Neuroscience*, **2013**, 7, 139	6.1	39
55	Metabotropic regulation of extrasynaptic GABAA receptors. *Frontiers in Neural Circuits*, **2013**, 7, 171	3.5	28
54	Intracerebral Human Microdialysis in Parkinson Disease. *Neuromethods*, **2013**, 209-223	0.4	
53	In Vivo Microdialysis to Study Striatal Dopaminergic Neurodegeneration. *Neuromethods*, **2013**, 23-42	0.4	0
52	Kv1.1 knock-in ataxic mice exhibit spontaneous myokymic activity exacerbated by fatigue, ischemia and low temperature. *Neurobiology of Disease*, **2012**, 47, 310-21	7.5	27
51	Redox sensitivity of tyrosine hydroxylase activity and expression in dopaminergic dysfunction. *CNS and Neurological Disorders - Drug Targets*, **2012**, 11, 419-29	2.6	16
50	Monitoring Dopamine in the Mesocorticolimbic and Nigrostriatal Systems by Microdialysis: Relevance for Mood Disorders and Parkinson's Disease **2011**, 93-150		
49	mGluR control of interneuron output regulates feedforward tonic GABAA inhibition in the visual thalamus. *Journal of Neuroscience*, **2011**, 31, 8669-80	6.6	31
48	Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. *CNS and Neurological Disorders - Drug Targets*, **2011**, 10, 777-91	2.6	28
47	The 5-HT2C Receptor Subtype Controls Central Dopaminergic Systems: Evidence from Electrophysiological and Neurochemical Studies **2011**, 215-247		1
46	Role of serotonin in central dopamine dysfunction. *CNS Neuroscience and Therapeutics*, **2010**, 16, 179-94	6.8	83
45	Critical role of nitric oxide on nicotine-induced hyperactivation of dopaminergic nigrostriatal system: Electrophysiological and neurochemical evidence in rats. *CNS Neuroscience and Therapeutics*, **2010**, 16, 127-36	6.8	14
44	Acute inactivation of the medial forebrain bundle imposes oscillations in the SNr: a challenge for the 6-OHDA model?. *Experimental Neurology*, **2010**, 225, 294-301	5.7	19

43	Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. *Journal of Neuroscience*, **2009**, 29, 8156-65	6.6	53
42	Effects of scopolamine on dopamine neurons in the substantia nigra: role of the pedunculopontine tegmental nucleus. *Synapse*, **2009**, 63, 673-80	2.4	12
41	Enhanced tonic GABAA inhibition in typical absence epilepsy. *Nature Medicine*, **2009**, 15, 1392-8	50.5	310
40	Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study. *Annals of the New York Academy of Sciences*, **2009**, 1155, 309-15	6.5	22
39	The unilateral nigral lesion induces dramatic bilateral modification on rat brain monoamine neurochemistry. *Annals of the New York Academy of Sciences*, **2009**, 1155, 316-23	6.5	25
38	Molecular and functional interactions between tumor necrosis factor-alpha receptors and the glutamatergic system in the mouse hippocampus: implications for seizure susceptibility. *Neuroscience*, **2009**, 161, 293-300	3.9	69
37	Electrophysiological and neurochemical characterization of 7-nitroindazole and molsidomine acute and sub-chronic administration effects in the dopaminergic nigrostrial system in rats. *Journal of Neural Transmission Supplementum*, **2009**, 173-82		1
36	In vivo microdialysis in Parkinson's research. *Journal of Neural Transmission Supplementum*, **2009**, 223-43		1
35	Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons. *Journal of Neural Transmission Supplementum*, **2009**, 333-41		10
34	A diet for dopaminergic neurons?. *Journal of Neural Transmission Supplementum*, **2009**, 317-31		2
33	Preferential Modulation of the GABAergic vs. Dopaminergic Function in the Substantia Nigra by 5-HT2C Receptor. *Advances in Behavioral Biology*, **2009**, 285-296		1
32	Serotonin-dopamine interaction: an overview. *Progress in Brain Research*, **2008**, 172, 3-6	2.9	58
31	Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. *Progress in Brain Research*, **2008**, 172, 7-44	2.9	122
30	Serotonin-dopamine interaction: electrophysiological evidence. *Progress in Brain Research*, **2008**, 172, 45-71	2.9	98
29	Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. *Progress in Brain Research*, **2008**, 172, 423-63	2.9	107
28	Serotonin-dopamine interaction: experimental evidence and therapeutic relevance. Preface. *Progress in Brain Research*, **2008**, 172, ix	2.9	14
27	Will it ever become possible to prevent dopaminergic neuronal degeneration?. *CNS and Neurological Disorders - Drug Targets*, **2008**, 7, 28-44	2.6	11
26	Prevention and Therapy of Neurodegenerative Disorders: Role of Nutritional Antioxidants **2007**, 621-661		8

25	Death in the substantia nigra: a motor tragedy. *Expert Review of Neurotherapeutics*, **2007**, 7, 677-97	4.3	36
24	The neurobiological bases for the pharmacotherapy of nicotine addiction. *Current Pharmaceutical Design*, **2007**, 13, 1269-84	3.3	45
23	Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. *Neuroscience*, **2007**, 144, 1523-35	3.9	79
22	Non-steroidal anti-inflammatory drugs in Parkinson's disease. *Experimental Neurology*, **2007**, 205, 295-312	3.7	170
21	Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. *Brain Research*, **2006**, 1095, 167-77	3.7	44
20	Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?. *Current Medicinal Chemistry*, **2006**, 13, 3069-81	4.3	47
19	Central serotonin2C receptor: from physiology to pathology. *Current Topics in Medicinal Chemistry*, **2006**, 6, 1909-25	3	74
18	SB 242084: A Selective 5-HT2C Receptor Antagonist. *CNS Neuroscience & Therapeutics*, **2006**, 6, 195-205		30
17	7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. *Annals of the New York Academy of Sciences*, **2006**, 1089, 462-71	6.5	29
16	Nitric oxide modulates striatal neuronal activity via soluble guanylyl cyclase: an in vivo microiontophoretic study in rats. *Synapse*, **2003**, 48, 100-7	2.4	18
15	Nitric oxide-induced inhibition on striatal cells and excitation on globus pallidus neurons: a microiontophoretic study in the rat. *Neuroscience Letters*, **2003**, 343, 101-4	3.3	14
14	CCK-nitric oxide interaction in rat cortex, striatum and pallidum. *Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology*, **2003**, 135, 425-33	3.2	1
13	Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT(2C) receptors in vivo. *Pharmacology Biochemistry and Behavior*, **2002**, 71, 607-13	3.9	46
12	Nitric oxide and cortico-striato-pallidal motor circuitry: Quantitative EEG analysis of surface and depth recordings. *Neuroscience Research Communications*, **2002**, 30, 121-133		13
11	Inhibition of nitric oxide synthase influences the activity of striatal neurons in the rat. *Neuroscience Letters*, **2002**, 325, 179-82	3.3	20
10	m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. *Neuroscience*, **2001**, 103, 111-6	3.9	120
9	Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. *Synapse*, **2000**, 35, 53-61	2.4	148
8	Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. *Brain Research*, **2000**, 865, 85-90	3.7	156

7	Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. *Psychopharmacology*, **2000**, 150, 45-51	4.7	54
6	Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. *Neuroscience*, **1999**, 91, 587-97	3.9	188
5	Reduced chaos of interspike interval of midbrain dopaminergic neurons in aged rats. *Neuroscience*, **1999**, 89, 1003-8	3.9	20
4	Decreased chaos of midbrain dopaminergic neurons after serotonin denervation. *Neuroscience*, **1999**, 92, 237-43	3.9	36
3	SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. *Neuropharmacology*, **1999**, 38, 1195-205	5.5	219
2	Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. *Brain Research Bulletin*, **1998**, 46, 547-54	3.9	90
1	Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. *Neuropharmacology*, **1998**, 37, 265-72	5.5	99